BB
Bradford Brinton
Senior Director Of Corporate Development at Medicenna Therapeutics Corp.
View Bradford's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Senior Director Of Corporate Development
Jul 2021 - Present · 3 years and 6 months
Sr. Manager, Licensing And Business Development
Oct 2019 - Jul 2021 · 1 years and 9 months
Ontario Centres of Excellence
Business Development And Commercialization Manager
Jun 2015 - Oct 2019 · 4 years and 4 months
Company Details
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
Year Founded
2012
Social Media
Linkedin
Industry
Biotechnology Research, Research, general, Research and testing, IT, Internet, R&D, Scientific Research and Development Services, Services
HQ Location
2 Bloor St W Toronto, Ontario M4W, CA
Keywords
cytokines and oncology
Discover More About Cleveland Clinic

Find verified contacts of Bradford Brinton in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.